Pliant Therapeutics, Inc. (PLRX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Bernard Jozef Coulie M.B.A., M.D., Ph.D.
|
President, CEO & Director | 938.9k | -- | 1966 |
|
Dr. Keith Lamont Cummings M.B.A., M.D.
|
Chief Financial Officer | 820.2k | -- | 1977 |
|
Ms. Minnie Kuo
|
Chief Operating Officer | 774.47k | -- | 1981 |
|
Dr. Rik Derynck Ph.D.
|
Scientific Founder & Member of Scientific Advisory Board | -- | -- | -- |
|
Mr. Dean Sheppard M.D.
|
Scientific Founder & Member of Scientific Advisory Board | -- | -- | -- |
|
Mr. Bill DeGrado Ph.D.
|
Scientific Founder | -- | -- | -- |
|
Mr. Hal Chapman M.D.
|
Scientific Founder & Member of Scientific Advisory Board | -- | -- | -- |
|
Ms. Delphine Imbert Ph.D.
|
Chief Technical Officer | -- | -- | -- |
|
Mr. Christopher S. Keenan
|
Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
|
Ms. Lily Cheung
|
Chief Human Resources Officer | -- | -- | 1973 |
Pliant Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 49
Description
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Corporate Governance
Upcoming Events
November 12, 2026 at 8:00 PM UTC
Pliant Therapeutics, Inc. Earnings Date
Recent Events
April 2, 2026 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
